Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Posts Earnings Results

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) posted its quarterly earnings data on Friday. The company reported $0.45 earnings per share (EPS) for the quarter, FiscalAI reports.

Calidi Biotherapeutics Trading Down 3.8%

Shares of Calidi Biotherapeutics stock traded down $0.01 during trading on Friday, hitting $0.27. 237,299 shares of the stock traded hands, compared to its average volume of 222,695. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.12 and a quick ratio of 2.12. Calidi Biotherapeutics has a 52 week low of $0.26 and a 52 week high of $19.20. The firm’s fifty day moving average is $0.71 and its 200-day moving average is $1.19.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CLDI. Virtu Financial LLC bought a new stake in shares of Calidi Biotherapeutics in the 4th quarter valued at about $25,000. DRW Securities LLC bought a new position in Calidi Biotherapeutics during the 4th quarter worth approximately $173,000. Geode Capital Management LLC increased its stake in Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after purchasing an additional 12,334 shares during the period. Finally, Warberg Asset Management LLC bought a new stake in Calidi Biotherapeutics in the third quarter valued at approximately $28,000. 12.53% of the stock is currently owned by institutional investors.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.